Back to Careers

The Wall Street Journal Discusses Juvena’s Series A and Its Potential to Expand the Range of Treatments for Chronic Conditions and Disease of Aging

Back to Careers

Juvena Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

Back to Careers

BioCom California, the leading life science industry organization in California recognizes Juvena’s CEO, Dr. Hanadie Yousef for her achievements, vision and scientific and business accumen in its Life Science Catalyst Awards.

Back to Careers

Juvena Therapeutics Awarded Highly Competitive 3.9M CIRM TRAN1 Grant to Advance Lead Program, JUV-161, to Treat Myotonic Dystrophy Type 1

Back to Careers

CIRM Awards Juvena a $3.9M TRAN1 Grant to Advance JUV-161 for Myotonic Dystrophy Type 1 (DM1)

Back to Careers

Juvena Therapeutics Interviewed– Embryonic Proteins for Tissue Regeneration- Jan 2020

Back to Careers

Juvena Therapeutics Listed as 1 of 3 Ground Breaking Longevity Startups

Back to Careers

CEO Hanadie Yousef’s Entrepreneurship Recognized by Spark at Stanford

Back to Careers

CEO Hanadie Yousef’s Most Recent Publication in Nature Medicine